Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsNewsAboutContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

News

Casimersen

(Amondys 45®)

Amondys 45®

Drug updated on 3/28/2024

Dosage FormInjection (intravenous; 100 mg/2 mL)
Drug ClassAntisense oligonucleotides
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Casimersen (Amondys 45) is designed to bypass frameshift DMD mutations and produce internally truncated, yet functional, dystrophin protein in patients amenable to exon 45 skipping.
  • One Randomized Controlled Trial document was reviewed for this analysis which focused on the safety, tolerability and plasma pharmacokinetics of casimersen (Amondys 45).
  • The trial enrolled a total of 12 participants aged between 7-21 years who had limited ambulation or were nonambulatory due to Duchenne muscular dystrophy (DMD).
  • During the double-blind dose titration phase of the study, participants were randomized into two groups with one receiving weekly casimersen infusions at escalating doses while the other received placebo.
  • Treatment-emergent adverse events occurred in all participants but they were mostly mild and unrelated to casimersen; there were no deaths or serious AEs related to its use indicating that it was well tolerated by patients with DMD amenable to exon 45 skipping.
  • Plasma exposure from casimersen increased proportionally with dosage without any suggestion of accumulation over time suggesting consistent pharmacokinetic properties across different dosages used during treatment periods up till week sixty.

Product Monograph / Prescribing Information

Document TitleYearSource
Amondys 45 (casimersen) Prescribing Information.2023Sarepta Therapeutics, Inc. Cambridge, MA

Randomized Controlled Trials

Document TitleSex DistributionYearSource
Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: a randomized, double‐blind, placebo‐controlled, dose‐titration trial.
12Subjects
F: 0%
M: 100%
2021Muscle & Nerve

Document Title

Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: a randomized, double‐blind, placebo‐controlled, dose‐titration trial.

Sex Distribution:

F:0%
M:100%
12Subjects

Year:

2021

Source:Muscle & Nerve